Global Blood Therapeutics Inc. reported positive results in a trial of a treatment for sickle cell disease on Wednesday, and said it met with the U.S. Food and Drug Administration in June regarding potential accelerated approval. Sickle cell anemia predominantly affects African-American patients and is an inherited condition, in which their red blood cells become shaped like sickles, preventing blood flow and causing painful attacks, fatigue, organ damage, stroke and more. The company said the Phase 3 trial called HOPE (Hemoglobin Oxygen Affinity Modulation to Inhibit HbS PolymErization), sought to evaluate voxelotor at 1500 mg and 900 mg doses after 12 weeks of treatment. The trial found a statistically significant increase in hemoglobin versus baseline for 58% of the 154 patients studied. Chief Executive Ted Love said the results were “highly encouraging,” and that the company believes they qualify for accelerated approval. Global Blood shares were halted for the news, but are down 1.7% in 2018 through Tuesday, while the S&P 500 has gained 1.9%.